我們已在上線！進一步了解

SLBT

SL Science Holding Ltd

SLBT

市值 US$8.58億

1.53 USD

-0.02

1.29%

收盤時已更新 10月16日下午4:00 EDT

1天

-1.29%

5天

4.08%

1個月

-15.47%

3個月

-64.67%

6個月

-54.05%

今年迄今

-54.05%

1年

-54.05%

5年

-54.05%

10年

-54.05%

關於： SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

員工： 20

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 80%

負面 20%

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy's ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered human trials, with a very low probability of success. With only $9M in cash, a $3.82M annual loss, and going-concern doubts, imminent dilution is almost certain without a major partnership.

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that its management team rang Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to celebrate its first quarter as a publicly traded company.

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. (“JY BioMed”), the intellectual property holder of the GDT platform and SL Science's licensor.

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about the product

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday.

SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday's Pre-Market Session

查看新聞排名

價格圖表採用Lightweight Charts™實作